Current Report Filing (8-k)
September 17 2015 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR
15(d) of The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): September 16, 2015
IMPRIMIS PHARMACEUTICALS,
INC.
(Exact name of registrant as
specified in its charter)
Delaware |
|
001-35814 |
|
45-0567010 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
12264
El Camino Real, Suite 350 |
|
|
San Diego, CA |
|
92130 |
(Address of principal
executive offices) |
|
(Zip Code) |
Registrant’s telephone
number, including area code: (858) 704-4040
12264
El Camino Real, Suite 350
San Diego, CA 92130 |
(Former name or former
address if changed since last report.) |
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
[ ] |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
[ ] |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD
Disclosure
Attached as Exhibit 99.1 to
this Item 7.01 is a presentation that is being used by the management of Imprimis Pharmaceuticals, Inc. (the “Company”)
in meetings and at conferences describing the Company.
The information contained
in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements
and Exhibits
(d)
|
Exhibits |
|
|
99.1 |
Presentation dated
September 2015 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
IMPRIMIS PHARMACEUTICALS,
INC. |
|
|
|
Dated: September 17,
2015 |
By: |
/s/
Andrew R. Boll |
|
Name: |
Andrew R. Boll |
|
Title: |
Chief Financial Officer |
EXHIBIT INDEX
99.1 |
Presentation dated
September 2015 |
![](image_001.jpg)
![](image_003.jpg)
![](image_004.jpg)
![](image_005.jpg)
![](image_006.jpg)
![](image_007.jpg)
![](image_008.jpg)
![](image_009.jpg)
![](image_010.jpg)
![](image_011.jpg)
![](image_012.jpg)
![](image_013.jpg)
![](image_015.jpg)
![](image_017.jpg)
![](image_018.jpg)
![](image_019.jpg)
![](image_020.jpg)
![](image_023.jpg)
![](image_024.jpg)
![](image_025.jpg)
![](image_026.jpg)
![](image_027.jpg)
![](image_028.jpg)
![](image_029.jpg)
![](image_031.jpg)
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Jul 2023 to Jul 2024